Yosef Landesman

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 655 citations · Full text

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 324 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +4

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Y-T Tai, Yosef Landesman, Chirag Acharya et al. · Leukemia · 2013 · 299 citations · Full text

Tumor Biology, Oncology, Bone Morphogenic Protein +10

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Albiruni R. Abdul Razak, Morten Mau‐Sørensen, Nashat Gabrail et al. · Journal of Clinical Oncology · 2016 · 244 citations · Full text

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Jimi Kim, Elizabeth A. McMillan, Hyun Seok Kim et al. · Nature · 2016 · 207 citations · Full text

Tumor Biology, Xpo1-dependent Nuclear Export, Oncology +10